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Available onlineSee page 1181 for the editorial comment on this articleAims Due to a lack of clinical trials, scientific evidence regarding the management of
patients with chronic heart failure and preserved left ventricular function (PLVF) is
scarce. The EuroHeart Failure Survey provided information on the characteristics,
treatment and outcomes of patients with PLVF as compared to patients with a left
ventricular systolic dysfunction (LVSD).
Methods and results We performed a secondary analysis using data from the Euro-
Heart Failure Survey, only including patients with a measurement of LV function
ðn ¼ 6806Þ. We selected two groups: patients with LVSD (54%) and patients with a
PLVF (46%). Patients with a PLVF were, on average, 4 years older and more often
women (55% vs. 29%, respectively, p\0.001) as compared to LVSD patients, and were
more likely to have hypertension (59% vs. 50%, p < 0:001) and atrial fibrillation (25%
vs. 23%, p ¼ 0:01). PLVF patients received less cardiovascular medication compared
to PLVF patients, with the exception of calcium antagonists. Multivariate analysis
revealed that LVSD was an independent predictor for mortality, while no differences
in treatment effect on mortality between the two groups was observed. A sensitivity
analysis, using different thresholds to separate patients with and without LVSD re-
vealed comparable findings.
Conclusions In the EuroHeart Failure Survey, a high percentage of heart failure pa-
tients had PLVF. Although major clinical differences were seen between the groups,
morbidity and mortality was high in both groups.c 2004 Published by Elsevier Ltd on behalf of The European Society of Cardiology.
KEYWORDS
Heart failure;
Preserved left ventricular
function;
Left ventricular systolic
dysfunction;
EuroHeart survey* Corresponding author.
E-mail address: michel.komajda@psl.ap-hop-paris.fr (M. Komajda).
y doi:10.1016/j.ehj.2004.05.021.
0195-668X/$ - see front matter c 2004 Published by Elsevier Ltd on behalf of The European Society of Cardiology.
doi:10.1016/j.ehj.2004.06.006
Differences between patients wih a preserved and a depressed left ventricular function 1215Introduction
Chronic heart failure is a major health problem and is
associated with high morbidity and mortality.1;2 Ad-
vances in therapy over the last two decades have proved
highly effective in reducing morbidity and mortality
rates. As a result, several effective treatment strategies
are now available, including b-blockers and ACE-inhibi-
tors, which have contributed to improved outcome in the
real world.3;4 However, most clinical investigations in
chronic heart failure focussed on patients with left
ventricular systolic dysfunction (LVSD). Consequently,
scientific evidence regarding the management of pa-
tients with preserved left ventricular function (PLVF) is
scarce.
To support physicians in everyday clinical decision-
making, the European Society of Cardiology (ESC) pub-
lished guidelines for the investigation and treatment of
heart failure patients.5;6 Since guidelines are intended to
be evidence-based, treatment recommendations for pa-
tients with PLVF remain mainly speculative.5 Still, it
should be realised that these patients constitute a size-
able group; it is estimated that 30% to 50% of all heart
failure patients do not have LVSD.7 The EuroHeart Failure
Survey was designed to evaluate to what extent treat-
ment guidelines are implemented in clinical practice. A
total of 10 701 suspected or confirmed heart failure pa-
tients were enrolled, of whom 3148 had PLVF. The survey
provided a wealth of information on patient character-
istics, diagnosis and treatment.8;9 We aimed to describe
to what extent the presence or absence of LVSD influ-
enced patient profile, management and outcome.Methods
The EuroHeart Failure Survey was the second in a series of sur-
veys that were conducted under the umbrella of the EuroHeart
Survey Program, which aimed to investigate the implementation
of treatment guidelines in clinical practice. The design details of
the Heart Failure Survey, which was undertaken during March
2000 and May 2001, were published previously.9;10 In short, all
consecutive discharges and deaths in the departments of car-
diology, cardiovascular surgery, general internal medicine and
geriatrics were screened over a 6-week period. The design of the
EuroHeart Failure survey included 115 hospitals from 24 ESC
member countries on a voluntary basis, including general hos-
pitals and university centres.
Patients were enrolled if they fulfilled at least one of the
following criteria were enrolled:
(1) a clinical diagnosis of heart failure during the admission;
(2) a diagnosis of heart failure recorded at any time in the last
three years;
(3) administration of a loop diuretic for any reason other than
renal failure during 24 h of death or discharge;
(4) pharmacological treatment for heart failure or ventricular
dysfunction within 24 h of death or discharge.
In all 10 701 enrolled patients, data were collected on co-
morbid conditions including hypertension, diabetes, chronic
atrial fibrillation and renal insufficiency. A clinical follow-up was
performed, and vital status (dead or alive) was determined at 12
weeks after discharge. We also collected data on re-admis-
sion(s). Surviving patients were then invited for an interview.During this visit, the NYHA classification was determined, and
the quality-of-life was measured with, among other matters, the
following question, “How would you rate your quality-of-life”,
using a 7-point rating scale (0¼ poor, 7¼ excellent).
This analysis included patients who had undergone a quan-
titative or qualitative assessment of the left ventricular function
(n ¼ 6806, 64% of the entire cohort). Of these patients, 80%
(n ¼ 5451) reported left ventricular ejection fraction (LVEF).
Patients with a LVEF P40%, as well as patients with a normal or
mildly depressed systolic left ventricular function, as assessed
by echocardiography were classified as PLVF. Patients with a
LVEF <40%, patients with a moderate or severe left ventricular
systolic dysfunction, and those with left ventricular dilatation,
as assessed by echocardiography were classified as LVSD.
Statistical analysis
Continuous variables are described as mean values with their
corresponding standard deviations, or as median values and
corresponding 25th and 75th percentiles. Dichotomous variables
are reported as absolute numbers and percentages. To evaluate
the characteristics of differences in treatment and outcome
between patients with and without LVSD, v2 tests, Student’s
t-tests or Mann Whitney U tests were applied as appropriate.
Multivariable logistic regression analysis was applied to study
the relationship between LVF and all-cause mortality during the
12-week follow-up period. LVSD, age, gender, hypertension,
diabetes, ischaemic heart disease, renal insufficiency, prior
stroke, chronic atrial fibrillation and pharmacological treatment
were forced into the regression model. We report odds ratios
(OR) and corresponding 95% confidence intervals (CI). To ex-
amine the differential effect of pharmacological treatment in
patients with and without LVSD, interaction terms were included
in the regression model. All calculations were performed using
SPSS 10.1 software package. For all tests a p value of 0.05 or less
(two-sided) was considered statistically significant.
We acknowledge the fact that the discussion on how to de-
fine preserved left ventricular function in patients with heart
failure is still ongoing, and that choice may be challenged.11–14
Therefore, we repeated all analyses using different thresholds.
We first analysed quantitative LVEF <40% vs. LVEF P40% (ex-
cluding patients with only qualitative assessment of the LV
function), and secondly LVEF <40% vs. LVEF >50% (excluding
patients with a LVEF P40% and 650%). Since the results of
these analyses were highly consistent, we only report on our
original choice.Results
Patient characteristics
Themean age (SD) of the 6806 patients was 69 (±13) years
and 41% were female. A substantial proportion of patients
had ischaemic heart disease (64%), a history of hyper-
tension (54%), documented diabetes (27%) or chronic at-
rial fibrillation (24%). The median duration of the index
hospitalisation was 10 days (interquartile range: 6–16).
Patients not in the analysis ðn ¼ 3895Þ were older and
included more females. Fewer patients were known with
an ischaemic heart disease, while a history of stroke was
more common in these patients. Furthermore, out of the
analyses, most patients (68%) were admitted to a general
internal medicine ward, as compared to the patients who
Table 1 Differences in characteristics of patients with preserved and depressed left ventricular function
Patients with known left ventricular function Patients not in the
analysis ðn ¼ 3895Þ
PLVF ðn ¼ 3148Þ LVSD ðn ¼ 3658Þ pa
Age (mean, SD) 71± 12 67± 13 <0.001 76± 11.6
Women (%) 1739 (55) 1065 (29) <0.001 2216 (57)
Men >70 years (%) 666 (21) 961 (26) <0.001 1039 (27)
Women >70 years (%) 1099 (35) 607 (17) <0.001 1748 (45)
Co-morbidity
Hypertension (%) 1845 (59) 1829 (50) <0.001 2005 (52)
Diabetes mellitus (%) 816 (26) 1016 (28) 0.09 1075 (28)
Ischaemic heart disease (%) 1851 (59) 2508 (69) <0.001 2060 (53)
Previous revascularisation (%) 377 (12) 674 (18) <0.001 291 (8)
Renal insufficiency (%) 155 (5) 220 (6) 0.05 296 (8)
Prior stroke (%) 492 (16) 501 (14) 0.02 814 (21)
Chronic atrial fibrillation (%) 795 (25) 827 (23) 0.01 860 (22)
LVEF (mean, SD) 56± 9.8 33± 10.9 <0.001 n.a.
Speciality at admission (%) <0.001
General internal medicine 1299 (42) 1164 (32) 2659 (68)
Cardiology/cardiovascular surgery 1615 (51) 2288 (63) 769 (20)
Other 231 (7) 197 (5) 458 (12)
Duration of index hospitalisation in days
(median, IQR)
10 (6–16) 10 (6–15) 0.26 9 (5–14)
Contribution of heart failure to index
admission (%)
1189 (38) 1904 (52) <0.001 1141 (29)
LVEF, left ventricular ejection fraction.
a The p value refers to the statistical difference between PLVF and LVSD.
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patients with and without LVSD revealed that almost half
of all patients (n ¼ 3148, 46%) had PLVF. Patients with
PLVF were on average 4 years older and more often
women (55% vs. 29%, p < 0:001) than patients with LVSD
(Table 1). Patients with PLVF were also more likely to
have a history of hypertension (59% vs. 50%, p < 0:001)
and chronic atrial fibrillation (25% vs. 23%, p ¼ 0:01),
whereas ischaemic heart disease (59% vs. 69%, p < 0:001)
was more prevalent in those with LVSD. Patients with
PLVF were more likely to be hospitalised in general in-
ternal medicine than those with LVSD (42% vs. 32%,
p < 0:001) and contribution of heart failure to index
admission was less prominent (38% vs. 52% p < 0:001).
Pharmacological treatment
Table 2 gives an overview of the pharmacological treat-
ment during hospitalisation in patients with or without
LVSD. The vast majority of patients received diuretics
(87% vs. 85%, p ¼ 0:01), most often loop diuretics. The
use of loop diuretics was the sole enrolment criterion in
5% of all patients (2% and 10% in patients with and
without LVSD, respectively). Patients with LVSD were
more likely to receive ACE-inhibitors or Angiotensin II
receptor blockers (ARBs) (82% versus 62% in PLVF,
p < 0:001), as well as b-blockers (46% and 39%,
p < 0:001) or cardiac glycosides (41% vs. 31%, p < 0:001).
Calcium channel blockers was the only class of agents
that was prescribed significantly more often in patientswith PLVF than in patients with LVSD (28% vs. 16%,
p < 0:001).
Pharmacological treatment
(multivariable analysis)
Patients receiving ACE-inhibitors had lower 12-week
death rates than those not receiving ACE-inhibitors (OR
0.55, 95% CI 0.43-0.71; Fig. 1). Similar results were ob-
served in relation to treatment with b-blockers (OR 0.61,
95% CI 0.48-0.77) and statins (OR 0.59, 95% CI 0.43-0.81).
In contrast, treatment with IV inotropic agents was as-
sociated with worse outcome (OR 5.53, 95% CI 4.07-
6.95). Patients receiving cardiac glycosides, diuretics
and nitrates had similar 12-week mortality as those not
receiving these agents. Of particular interest was the
lack of statistical evidence for a heterogeneous effect of
any agent between patients both with and without LVSD
(P for interaction, all >0.05).
Outcome
The incidence of all-cause mortality during the 12-week
follow-up, although high in both groups, was higher in
patients with LVSD than those without (12% vs. 10%, OR
1.35, 95% CI 1.13–1.62). No significant differences were
observed in the need for re-admission (22% versus 21%),
time to first re-admission or number of days that patients
were hospitalised during the follow-up period (Table 3).
NYHA classification at follow-up did not differ between
Table 2 Differences in pharmacological treatment between patients preserved and depressed left ventricular function
PLVF ðn ¼ 3148Þ LVSD ðn ¼ 3658Þ p
ACE-inhibitors (%) 1839 (58) 2848 (78) <0.001
Angiotensin II receptor blockers (%) 140 (4) 218 (6) 0.005
ACE or ARB (%) 1956 (62) 3009 (82) <0.001
b-Blockers (%) 1231 (39) 1679 (46) <0.001
Calcium channel blockers (%) 867 (28) 583 (16) <0.001
Cardiac glycosides (%) 986 (31) 1512 (41) <0.001
Diuretics (%) 2679 (85) 3188 (87) 0.01
Loop diuretic (%)a 2431 (91) 2952 (93) 0.01
Thiazide diuretic (%)a 343 (13) 381 (12) 0.32
i.v. inotropic agents (%) 204 (7) 380 (10) <0.001
Nitrates (%) 1451 (46) 1811 (50) 0.005
Spironolactone (%) 527 (17) 1070 (29) <0.001
Statins (%) 668 (21) 937 (26) <0.001
a The proportions may add up more than 100% as some patients received both diuretics.
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Fig. 1 All cause mortality with respect to pharmacological treatment.
Adjusted for age, gender, hypertension, diabetes, ischaemic heart dis-
ease, renal failure, prior stroke, chronic atrial fibrillation and pharma-
cological treatment. LVSD: left ventricular systolic dysfunction PLVF:
preserved left ventricular function.
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III/IV, respectively). More patients with LVSD (29%)
viewed their quality of life as “quite poor” to “very poor”
as compared to 23% in the preserved group ðp ¼ 0:04Þ.
Outcome (multivariate analysis)
After adjustment for age, gender, co-morbidity and
pharmacological treatment, patients with LVSD had
higher mortality than patients with PLVF (OR 1.4, 95% CI
1.1-1.6, p ¼ 0:001). No differential effect of the pres-
ence or absence of left ventricular systolic function on
all-cause mortality was observed in subgroups of patients
according to clinical characteristics, except for diabetes
ðp ¼ 0:03Þ (Fig. 2).Discussion
Almost half of heart failure patients enrolled in the
EuroHeart Failure Survey with left ventricular function
determination had preserved left ventricular function.
This group of patients had different patient character-
istics to that of patients with LVSD, including advanced
age, a higher proportion of women, and a history of hy-
pertension and chronic atrial fibrillation. Furthermore
we observed a higher mortality in patients with LVSD, but
mortality was high in both groups.
Our findings are in agreement with prior reports sug-
gesting that patients with LVSD are at increased risk for
mortality.15–21 However, there is growing recognition
that heart failure caused primarily by abnormalities in
relaxation/diastole represents a substantial proportion
of all heart failure patients and is also associated with a
high morbidity and mortality. We showed that 12-week
mortality was high in both groups, whereas every fifth
patient, regardless of LV function, was re-admitted
within 12 weeks. In the recently published CHARM-Pre-
served trial, 24% of patients in the placebo arm experi-
enced a composite endpoint of cardiovascular death or
hospital admission for heart failure, while 18.5% of these
patients were hospitalised for heart failure over 36.6
months of follow-up.22 The cardiovascular mortality
among these patients was 58% lower than in CHARM pa-
tients with low LVEF <40%.23;24
The definition of heart failure with preserved systolic
function or diastolic heart failure remains a matter of
controversy12;25 and a difficult exercise in clinical prac-
tice. This probably explains why clinical trials have been
lacking and guidelines on the management of this subset
of patients remain mainly speculative.6 So far, only a
subset of patients enrolled in the DIG trial with EF >45%
and the CHARM preserved arm have extensively studied
the effect of Digoxin and Candesartan, respectively in
PLVF patients. Digoxin reduced heart failure hospitali-
sations and the Angiotensin II receptor blockers (ARB)
reduced cardiovascular hospitalisations in these tri-
als.22;26 Our analysis on the large EuroHeart Failure
Table 3 Differences in outcome between patients with preserved and depressed left ventricular function
PLVF ðn ¼ 3148Þ LVSD ðn ¼ 3658Þ p
Total mortality (%)a 307 (10) 425 (12) 0.01
Re-admission <12 weeks (%) 676 (22) 759 (21) 0.47
Time to 1st re-admission in days (median, IQR) 29 (10–54) 28 (10–53) 0.66
Hospitalisation time in days during follow-up (median, IQR) 11 (6–22) 11 (5–22) 0.30
12-week follow-up interviewb (n, %) 1124 (36) 1304 (36)
NYHA classification 0.64
Class I/II (%) 844 (76) 965 (75)
Class III/IV (%) 270 (24) 327 (25)
Quality-of-life 0.04
Very good–quite good (%) 516 (46) 545 (42)
Average (%) 340 (30) 380 (29)
Quite poor–very poor (%) 257 (23) 369 (29)
NYHA, New York Heart Association classification.
a Patients who died during index hospitalisation or within the 12-week follow-up period.
b Only patients who attended the 12-week follow-up interview.
0.1 1 10
0.97
0.35
0.03
P for interaction
Age
Hypertension
Diabetes Mellitus
Characteristics Category
Renal insufficiency
Gender
0.07
0.70
Ischaemic Heart Disease 0.22
All-cause mortality
Prior stroke 0.75
Men
Women
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Chronic Atrial Fibrillation Yes
No 0.86
<
 70
> 70
All LVSD better PLVF better 
n=3455 
n=3346
n=3974 
n=2804
n=3674 
n=3086
n=1832 
n=4967 
n=4359 
n=2443
n=375 
n=6029
n=993 
n=5808
n=1622 
n=5032
Fig. 2 Relation between left ventricular systolic function and mortality
in subgroup of patients according to patient characteristics. Adjusted for
age, gender, hypertension, diabetes, ischaemic heart disease, renal
failure, prior stroke, chronic atrial fibrillation and pharmacological
treatment.
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specific clinical profile of patients with PLVF and the way
these patients are treated in Europe.
We included only patients with a known LV function,
thus excluding 3895 patients (36%) of whom we had no
information in this context. However, according to the
guidelines, echocardiography is encouraged in all heart
failure patients.5;6 The high percentage of patients who
could not be included in this secondary analysis reflects
the lack of this diagnostic procedure in patients with
proven or suspected heart failure.
As discussed in the main article of the EuroHeart
Failure Survey8, adherence to the guidelines regarding
ACE-inhibitors was observed in a majority of patients
with a documented ventricular dysfunction, whereas
treatment with b-blockers was clearly under-prescribed.
As mentioned earlier, treatment guidelines lack evi-dence-based recommendations for patients with a pre-
served left ventricular function. It is therefore not
possible to compare the treatment of these patients with
the guidelines. Moreover, since more patients with PLVF
were hospitalised in general internal medicine as com-
pared to those with LVSD, this could clearly affect
management. Although there is currently no evidence
available from randomised controlled trials on treatment
of patients with a preserved LVF with ACE-inhibitors or b-
blockers, a considerable percentage of these patients
were treated with the above mentioned drugs (58% and
39%, respectively). For ACE-inhibitors, the rate of pre-
scription among this hospitalised preserved LVF group
compares favourably to the rate reported in CHARM
Preserved (58% vs. 18.6%) whereas the use of b-blockers
(39% vs. 55.5%) was lower than in the clinical trial.22 In
CHARM preserved there was a statistically marginal ef-
fect of the ARB candesartan on the outcome of cardio-
vascular mortality or heart failure hospitalisations.
However, the total number of these hospitalisations,
both for patients and episodes, was significantly reduced
in this trial. The use of cardiac glycosides was signifi-
cantly lower in the PLVF group although the rate of atrial
fibrillation was slightly greater in the LVSD group. The
relatively high rate of prescription of calcium channel
blockers in the preserved group, one of the few drugs
that are (according to the guidelines) indicated in this
subgroup of patients, probably reflects the greater pro-
portion of patients with a history of hypertension.
This study is the first to compare the effects of
pharmacological treatment in patients with or without
LVSD. We would like to stress however, that one should
be very cautious in interpreting these observational data.
Use of ACE-inhibitors or b-blockers was associated with
improved survival, reflecting either the effects of
treatment or patient selection. Therapy with diuretics,
cardiac glycosides and nitrates seemed to have no in-
fluence on mortality, whereas those treated with an in-
travenous inotropic agent had a worse prognosis
Differences between patients wih a preserved and a depressed left ventricular function 1219indicating the poor clinical condition of patients needing
intravenous support with these drugs. Interestingly, this
analysis revealed no interaction between the apparent
effects of treatment on mortality and the presence or
absence of LVSD.
Our study also observed the sub-optimal use of diag-
nostic procedures to evaluate LVF in daily practice, as
3895 patients were left out of this analysis due to the
absence of this evaluation. Knowing the cardiac function
is of great importance, as the guidelines primarily focus
on heart failure patients with LVSD.6 Given the limited
number of randomised trials conducted in PLVF patients,
the treatment of these patients is referred to as highly
speculative. Several ongoing trials specifically address
the interest of b-blockers (SENIOR), ACE-Inhibitors (PEP
{CHF} or ARBs {I-Preserve}) in the setting of patients with
preserved systolic function. Taking this into account one
could argue that a large majority of the 10701 patients in
the EuroHeart Failure Survey did not receive evidence-
based treatment. This was mainly due to the missing
evidence of cardiac dysfunction and the absence of evi-
dence-based treatment aiming at PLVF patients. In order
to provide optimal treatment to all heart failure pa-
tients, we should be more aware of the under-utilisation
in evaluating the LVF. Furthermore, we would like to
stress that the observed absence of a heterogeneous
effect between patients with or without LVSD does not
mean that patients with PLVF will derive the same ben-
efit from pharmacological treatment as those with LVSD.
This observation deserves confirmation in randomised
trials. Thus the evaluation of LVF remains an area for
improvement.
This study has certain limitations that should be taken
into account when interpreting the results. It should be
noted that surveys like the EuroHeart Failure Survey are
prone to information and selection bias. Since a limited
number of centres were recruited across the 24 coun-
tries, interpretation of the results must be cautious due
to a potential centre effect. However our findings, with
respect to the proportion of patients with PLVF and use
of various treatments, were in agreement with the IM-
PROVEMENT survey, which was performed by primary
care physicians in the same European countries.27
Furthermore, we acknowledge the fact that only
64% of our overall population had undergone an as-
sessment of the left ventricular function and cannot
exclude selection bias, as the excluded patients
slightly differed from those in the analysis. Neverthe-
less, our findings regarding patients with heart failure
are in line with other observational studies.15–17;21 By
design, the EuroHeart Failure survey included clusters
of university hospitals and general hospitals. We cannot
therefore extend our observation to the overall heart
failure population as this selection of centres might
impact on the patients’ profile and treatment modali-
ties. The selection of patients studied here was based
on the record of the value of ejection fraction what-
ever the method used. We also used an arbitrary
threshold of 40% to separate depressed and preserved
or mildly reduced systolic function. However, a sensi-
tivity analysis showed comparable results whatever thethreshold for ejection fraction used. Finally, the im-
pact of the various cardiovascular medications was
made in the context of an observational study, not of a
randomised trial.
In conclusion, this study showed that a high per-
centage of hospitalised heart failure patients had PLVF.
Although major statistical differences exist regarding
clinical characteristics and treatment, morbidity and
mortality was high in both groups. A considerable num-
ber of patients in the preserved group were treated with
drugs (ACE-inhibitors and b-blockers) that have a docu-
mented impact on survival in patients with a depressed
LV systolic ventricular function. Although there was still
under-utilisation of these drugs according to the guide-
lines in the depressed group, far more patients in this
group received ACE-inhibitors or b-blockers compared to
patients with a preserved ventricular function. Finally,
only a limited number of patients were treated by ARBs
in both groups. A comparison of the effect of pharma-
cological treatment, in the context of an observational
study did not reveal an interaction of the treatment
effect on mortality between LVSD and PLVF.References
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